Beijing Aosaikang Pharmaceutical Co., Ltd.
SZSE:002755.SZ
8.79 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,777.642 | 1,443.46 | 1,872.572 | 3,106.667 | 3,782.689 | 4,518.632 | 3,931.882 | 365.934 | 178.358 | 278.157 | 470.869 | 500.425 | 494.258 | 529.171 |
| Cost of Revenue
| 331.649 | 277.051 | 243.605 | 277.053 | 311.441 | 336.211 | 277.773 | 268.368 | 144.066 | 186.433 | 343.925 | 363.504 | 348.603 | 393.897 |
| Gross Profit
| 1,445.993 | 1,166.409 | 1,628.967 | 2,829.613 | 3,471.247 | 4,182.42 | 3,654.109 | 97.566 | 34.291 | 91.724 | 126.944 | 136.92 | 145.656 | 135.274 |
| Gross Profit Ratio
| 0.813 | 0.808 | 0.87 | 0.911 | 0.918 | 0.926 | 0.929 | 0.267 | 0.192 | 0.33 | 0.27 | 0.274 | 0.295 | 0.256 |
| Reseach & Development Expenses
| 177.324 | 474.851 | 588.838 | 324.447 | 255.891 | 310.104 | 290.268 | 18.068 | 8.929 | 18.188 | 13.291 | 19.445 | 16.23 | 0 |
| General & Administrative Expenses
| 54.979 | 55.594 | 46.165 | 52.852 | 51.837 | 63.066 | 55.191 | 11.732 | 4.726 | 6.625 | 6.945 | 7.008 | 8.737 | 41.703 |
| Selling & Marketing Expenses
| 1,009.816 | 815.427 | 1,193.719 | 1,998.085 | 2,280.901 | 2,791.309 | 2,428.98 | 8.874 | 6.767 | 6.219 | 6.734 | 6.709 | 7.027 | 9.488 |
| SG&A
| 1,064.795 | 871.021 | 1,239.885 | 2,050.937 | 2,332.738 | 2,854.375 | 2,484.171 | 20.607 | 11.493 | 12.844 | 13.679 | 13.718 | 15.763 | 51.191 |
| Other Expenses
| 46.929 | 43.257 | 82.689 | 98.548 | 132.502 | 157.509 | 10.455 | 0.421 | 0.04 | -0.803 | 0.35 | -0.153 | 0.457 | 0.579 |
| Operating Expenses
| 1,289.048 | 1,386.287 | 1,911.412 | 2,473.932 | 2,721.131 | 3,321.989 | 2,929.015 | 68.066 | 40.151 | 57.77 | 59.845 | 65.522 | 67.394 | 70.658 |
| Operating Income
| 156.944 | -290.49 | -282.445 | 402.511 | 790.302 | 871.998 | 744.479 | 19.922 | 1.339 | 22.769 | 44.637 | 65.401 | 70.578 | 57.252 |
| Operating Income Ratio
| 0.088 | -0.201 | -0.151 | 0.13 | 0.209 | 0.193 | 0.189 | 0.054 | 0.008 | 0.082 | 0.095 | 0.131 | 0.143 | 0.108 |
| Total Other Income Expenses Net
| -5.491 | 89.56 | 17.561 | 3.56 | 30.897 | 15.936 | 10.455 | 43.392 | 3.606 | 1.363 | 0.321 | 0.251 | 0.947 | 0.549 |
| Income Before Tax
| 151.453 | -200.929 | -262.504 | 406.071 | 821.198 | 887.933 | 754.934 | 20.343 | 4.645 | 23.017 | 44.958 | 65.653 | 71.269 | 57.802 |
| Income Before Tax Ratio
| 0.085 | -0.139 | -0.14 | 0.131 | 0.217 | 0.197 | 0.192 | 0.056 | 0.026 | 0.083 | 0.095 | 0.131 | 0.144 | 0.109 |
| Income Tax Expense
| 22.984 | 6.55 | 3.701 | 25.506 | 95.83 | 108.032 | 86.031 | 3.082 | 0.041 | 4.152 | 7.454 | 10.132 | 11.315 | 8.666 |
| Net Income
| 160.294 | -148.53 | -266.206 | 379.908 | 721.625 | 780.959 | 670.074 | 10.967 | 4.605 | 18.865 | 37.504 | 55.521 | 59.954 | 49.135 |
| Net Income Ratio
| 0.09 | -0.103 | -0.142 | 0.122 | 0.191 | 0.173 | 0.17 | 0.03 | 0.026 | 0.068 | 0.08 | 0.111 | 0.121 | 0.093 |
| EPS
| 0.17 | -0.16 | -0.29 | 0.41 | 0.78 | 0.84 | 0.89 | 0.8 | 0.029 | 0.12 | 0.29 | 0.43 | 0.46 | 0.38 |
| EPS Diluted
| 0.17 | -0.16 | -0.29 | 0.41 | 0.78 | 0.84 | 0.89 | 0.8 | 0.029 | 0.12 | 0.29 | 0.43 | 0.46 | 0.38 |
| EBITDA
| 241.699 | -112.746 | -163.563 | 498.402 | 913.651 | 977.088 | 838.531 | 772.183 | 8.828 | 27.194 | 46.845 | 67.566 | 82.416 | 72.325 |
| EBITDA Ratio
| 0.136 | -0.078 | -0.087 | 0.16 | 0.242 | 0.216 | 0.213 | 2.11 | 0.049 | 0.098 | 0.099 | 0.135 | 0.167 | 0.137 |